Abstract
A series of xanthine derivatives as potent dual ligands targeting DPP-IV and GPR119 was discovered through an approach of the merged pharmacophores of GPR119 agonists and DPP-IV inhibitor linagliptin. Systematic optimization of general structure 5 led to the identification of compound 20i with selective DPP-IV inhibition, good GPR119 agonism activity and favorable metabolic stability. Docking study was performed to elucidate the potent DPP-IV inhibition of 20i. Compound 20i may serve as a tool compound for further design of anti-diabetic drugs targeting both DPP-IV and GPR119.
Keywords:
DPP-IV; Dual ligands; GPR119; Merged pharmacophores; Xanthine derivatives.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Animals
-
Dipeptidyl Peptidase 4 / chemistry
-
Dipeptidyl Peptidase 4 / metabolism*
-
Dipeptidyl-Peptidase IV Inhibitors / chemistry
-
Dipeptidyl-Peptidase IV Inhibitors / metabolism
-
Dipeptidyl-Peptidase IV Inhibitors / pharmacology
-
Drug Discovery
-
Drug Stability
-
Humans
-
Hypoglycemic Agents / chemistry*
-
Hypoglycemic Agents / metabolism
-
Hypoglycemic Agents / pharmacology*
-
Mice
-
Molecular Docking Simulation
-
Protein Conformation
-
Receptors, G-Protein-Coupled / agonists*
-
Structure-Activity Relationship
-
Xanthine / chemistry*
-
Xanthine / metabolism
-
Xanthine / pharmacology*
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
GPR119 protein, human
-
Hypoglycemic Agents
-
Receptors, G-Protein-Coupled
-
Xanthine
-
DPP4 protein, human
-
Dipeptidyl Peptidase 4